Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 481 to 495 of 882 results for community guidance

  1. What are the benefits of planned, regular community-based reviews compared with as-required review of non-cancer patients approaching the end of their life?

    NG142/3 Question What are the benefits of planned, regular community-based reviews compared with as-required review of non-cancer...

  2. Modes of provision of support to healthcare professionals:- What would be the impact of dietetic telephone support to healthcare professionals to aid in the diagnosis and assessment of babies showing non-IgE-mediated food allergy symptoms in primary care and community settings?

    babies showing non-IgE-mediated food allergy symptoms in primary care and community settings? Any explanatory notes(if applicable) Why...

  3. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

    This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.

  4. Maintaining the benefits of early intervention in psychosis services after discharge:- How can the benefits of early intervention in psychosis services be maintained once service users are discharged after 3 years?

    acceptability and engagement. Once people are transferred to primary care or community mental health services these gains are...

  5. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  6. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation.

  7. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

  8. Mepolizumab for treating severe eosinophilic asthma (TA671)

    Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.

  9. Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)

    Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.

  10. Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

    Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.

  11. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

    This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.

  12. Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

    This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.

  13. Urethrotech UCD for difficult or failed catheterisation (MIB116)

    NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .